Suggestion of Tunisia's medical oncologist in the management of breast cancer during COVID-19 pandemic. (October 2020)

• Record Type: Journal Article
• Authors: Yahyaoui, Yosra; Ghodhbani, Zahra; Hamdi, Adel; Letaief, Feryel; Zenzri, Yosr; Ben Said, Azza; Blouza, Imen; Mezlini, Amel
• Is Part Of: Journal of oncology pharmacy practice. Volume 26:Number 7(2020)
• Page Start: 1732
• Page End: 1734
• Publication Date: 2020-10
• Subjects: COVID-19 -- breast cancer -- Tunisia -- chemotherapy -- medical oncology; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220948943
• Languages: English
• ISSNs: 1078-1552

Abstract

Cancer patients are at higher risk to be infected with COVID-19 and to develop a more severe form. Breast cancer (BC) treatments, including chemotherapy (CT), targeted therapy and immunotherapy can weaken the immune system and possibly cause lung problems. For all these reasons Salah Azaiez Institute's department of Medical Oncology took drastic actions to protect patients. In this article we will discuss protocol adjustments taken during the COVID-19 pandemic for breast cancer patients.